Skip to Content

Clinical Trial Details

Herceptin Use in DCIS

Phase 3 Study Comparing Radiation Therapy With or Without Herceptin for Her2-Positive Ductal Carcinoma In Situ (DCIS) Removed by Lumpectomy


The study will find out if adding Herceptin to breast radiation therapy is more effective than radiation therapy alone in preventing occurrence of breast cancer in the same breast, the other breast or in other parts of the body in patient who are Her2 neu positive. The study will test the tumor cells to determine eligibility. One group of woman would require two doses of IV Herceptin along with radiation therapy treatment. The other group would just receive radiation therapy which is the current standard of care.

IRB Protocol Number
Principal Investigator(s)
Charles Catcher, MD

Clinical Trial Categories

  • Breast Cancer
National Cancer Institute
Margaret White, RN OCN, CC at 603-232-8908


  • Payson Center for Cancer Care
    250 Pleasant Street
    Concord, NH 03301
    Main: 603-230-6000